GlobalData on MSN11d
Oncternal stock crashes by 60% as it lays off staff and scraps trialsOncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the ...
"It's not surprising to many of you that ibrutinib has been removed from the FDA label for ... Patel recently disclosed ties with a long list of pharmaceutical companies, including AbbVie, AstraZeneca ...
Medpage Today on MSN9d
Chemo-Free Triplet Yields 68% Response Rate in Richter TransformationRichter transformation involves the evolution of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) into an ...
Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL) that develops from B-lymphocytes and is generally slow-growing or ...
Richter transformation describes the development of an aggressive lymphoma in patients with chronic lymphocytic leukaemia, ...
Key mantle cell lymphoma companies such as AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou ... Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others are under ...
The competition in follicular lymphoma is rapidly intensifying, with three CAR-T therapies and three bispecific antibodies now approved for relapsed or refractory patients. As both classes of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback